EA201991192A1 - PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCER - Google Patents

PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCER

Info

Publication number
EA201991192A1
EA201991192A1 EA201991192A EA201991192A EA201991192A1 EA 201991192 A1 EA201991192 A1 EA 201991192A1 EA 201991192 A EA201991192 A EA 201991192A EA 201991192 A EA201991192 A EA 201991192A EA 201991192 A1 EA201991192 A1 EA 201991192A1
Authority
EA
Eurasian Patent Office
Prior art keywords
promoter
methods
inhibitor
subject
melanin
Prior art date
Application number
EA201991192A
Other languages
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/351,966 external-priority patent/US10272068B2/en
Application filed filed Critical
Publication of EA201991192A1 publication Critical patent/EA201991192A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Предоставлены фармацевтическая композиция и наборы, содержащие ингибитор тирозингидроксилазы; меланин, промотор меланина или их комбинацию; промотор A450 3A4; и ингибитор лейцинаминопептидазы. Предоставлены также способы лечения злокачественного новообразования у субъекта, включающие введение субъекту, нуждающемуся в этом, эффективного количества ингибитора тирозингидроксилазы, промотора меланина, промотора p450 3A4 и ингибитора лейцинаминопептидазы. Предоставлены также способы уменьшения пролиферации клеток у субъекта, включающие введение субъекту, нуждающемуся в этом, эффективного количества ингибитора тирозингидроксилазы, промотора меланина, промотора p450 3A4 и ингибитора лейцинаминопептидазы.A pharmaceutical composition and kits comprising a tyrosine hydroxylase inhibitor are provided; melanin, a melanin promoter, or a combination thereof; promoter A450 3A4; and a leucinaminopeptidase inhibitor. Methods are also provided for treating a malignant neoplasm in a subject, comprising administering to a subject in need thereof an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor. Methods are also provided for reducing cell proliferation in a subject, comprising administering to a subject in need thereof an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor.

EA201991192A 2016-11-15 2017-11-15 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCER EA201991192A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/351,966 US10272068B2 (en) 2012-01-17 2016-11-15 Pharmaceutical compositions and methods
PCT/US2017/061682 WO2018093820A1 (en) 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
EA201991192A1 true EA201991192A1 (en) 2019-10-31

Family

ID=60570232

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991192A EA201991192A1 (en) 2016-11-15 2017-11-15 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCER

Country Status (12)

Country Link
EP (1) EP3541411A1 (en)
JP (2) JP2019537608A (en)
KR (2) KR20190084291A (en)
CN (1) CN110167580A (en)
AU (1) AU2017361080A1 (en)
BR (1) BR112019009799A2 (en)
CA (1) CA3040922A1 (en)
EA (1) EA201991192A1 (en)
IL (1) IL266486A (en)
MX (1) MX2019005450A (en)
PH (1) PH12019500758A1 (en)
WO (1) WO2018093820A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
WO2021076723A1 (en) * 2019-10-15 2021-04-22 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
CA3167918A1 (en) * 2020-01-17 2021-07-22 Tyme, Inc. Compositions and methods for modulating cancer
CN111358777A (en) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 Method for improving mitochondrial function of peripheral blood mononuclear cells and application
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
US8481498B1 (en) * 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
LT2804599T (en) * 2012-01-17 2019-04-10 Tyme, Inc. Combination therapy for the treatment of cancer
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
AU2017361080A1 (en) 2019-05-02
BR112019009799A2 (en) 2019-08-06
PH12019500758A1 (en) 2019-07-24
WO2018093820A1 (en) 2018-05-24
CN110167580A (en) 2019-08-23
CA3040922A1 (en) 2018-05-24
JP2023018029A (en) 2023-02-07
IL266486A (en) 2019-07-31
KR20190084291A (en) 2019-07-16
KR20230003314A (en) 2023-01-05
JP2019537608A (en) 2019-12-26
EP3541411A1 (en) 2019-09-25
MX2019005450A (en) 2019-07-04

Similar Documents

Publication Publication Date Title
EA201991192A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCER
CY1121450T1 (en) COMBINATION TREATMENT FOR CANCER TREATMENT
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
CL2020002082A1 (en) PD-1 / PD-L1 inhibitors.
ZA202007007B (en) Mcl-1 inhibitors
DOP2019000266A (en) PD-1 / PD-L1 INHIBITORS
CL2021000084A1 (en) PD-1 / PD-L1 inhibitors
CO2018009275A2 (en) Spiro-condensed pyrrolidine derivatives as inhibitors of desubiquitinating enzymes (dub)
MX2022005216A (en) Pyridazinones as parp7 inhibitors.
MX2021011209A (en) Novel small molecule inhibitors of tead transcription factors.
EA201791516A1 (en) METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS
EA201890961A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT NORROFORMATION
EA201792204A1 (en) IDO INHIBITORS
BR112015011756A2 (en) glutamase inhibitors and methods of use
BR112017017700A2 (en) cancer treatment methods, compositions and kits
EA201300171A1 (en) METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY
EA201692480A1 (en) PHARMACEUTICAL COMPOSITION
EA201692483A1 (en) HYSTON METHYLASE INHIBITORS
SA519410093B1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
EA201891601A1 (en) METHODS AND COMPOSITIONS ENHANCED EFFICIENCY BY MEDIATED SUPERANTIGEN IMMUNOTHERAPY OF MALIGNANT TUMORS
EA202191257A1 (en) ANTI-CANCER THERAPY BASED ON IMMUNOCYTES BINDING LIV1
EA201791933A1 (en) INHIBITION OF OLIG2 ACTIVITY
BR112018068027A2 (en) method for treating cancer in a patient and pharmaceutical composition
EA201991305A1 (en) Tyrosine Derivatives and Compositions Including Theirs
EA201792288A1 (en) METHODS OF TREATING CANCER